SUPPORTING A THRIVING UK LIFE SCIENCES ECOSYSTEM

SUPPORTING A THRIVING UK LIFE SCIENCES ECOSYSTEM

ABOUT THE AMERICAN PHARMACEUTICAL GROUP THE AMERICAN PHARMACEUTICAL GROUP REPRESENTS THE TEN LARGEST US RESEARCH- BASED BIO-PHARMACEUTICAL COMPANIES WITH A PRESENCE IN THE UK. 1.2bn 792m (R&D) INVESTING IN BRITAIN APG member companies invest more than 1.2 BILLION annually in the UK. 1 792 MILLION of this is invested in research and development alone. 2 This represents 13% of the total spend by pharmaceutical companies in the UK 3 40 SITES ACROSS THE UK EMPLOYMENT IN THE UK The APG employ more than 14,000 PEOPLE in highly skilled jobs. 4 Each life sciences position supports 3.4 jobs elsewhere in the UK economy; this equates to 50,000 ROLES in total that link back to APG employers. ABOUT THE AMERICAN PHARMACEUTICAL GROUP The pharmaceutical industry plays an important role in improving Britain s health and supporting economic growth by developing innovative, life-saving medicines. The (APG) represents the ten largest US research-based bio-pharmaceutical companies with a presence in the UK. The works to promote a greater understanding of the value of our member companies to people s health, the UK life sciences ecosystem and the UK economy. We seek a receptive environment for inward investment that also encourages the appropriate access, uptake and use of innovative medicines in the NHS. The APG works to improve understanding of the industry, and the healthcare contribution of companies, amongst Government, the NHS and other interested stakeholders. Working closely with the industry s trade body, the Association of the British Industry, the APG brings a unique perspective to the policy debate, informed by its intrinsic link to the US, which accounts for over half of the developed world s research and development (R&D) and is the most competitive market for medicines in the world. AMERICAN COMPANIES COMMITTING TO MAKE THE UK THE LEADER IN LIFE SCIENCES The pharmaceutical industry is an important part of Britain s industrial heritage and a major source of investment. The ten companies that comprise the APG have a long-standing commitment to the UK and play a significant role in delivering the UK s life sciences capacity. APG member companies invest more than 1.2 billion annually in the UK 8, with 792 million invested in R&D alone 9. THE APG ACCOUNTS FOR 13% OF ALL SPEND BY PHARMACEUTICALS IN THE UK 10 APG member companies are at the forefront of developing innovative treatments for patients. These include medicines to treat rare diseases and conditions, such as mental health, cancer, rheumatoid arthritis, hypertension, alongside vaccinations. APG members have been responsible for launching over 20 new medicines in the UK between 2011 and 2015 13. In 2017 alone, APG members are conducting more than 500 clinical trials in the UK 14, providing over 24,000 patients 15 with the opportunity to benefit from the latest innovative medicines. PARTNERING FOR THE FUTURE APG members recognise that an effective life sciences ecosystem requires industry working in partnership with other members of the life sciences ecosystem to enable the sharing of knowledge, expertise and resources. We are working steadfastly to combat the biggest health challenges facing the world today. Since its launch in 2013, the Johnson & Johnson London Innovation Centre, of which Janssen belongs to, has driven 40 collaborations in the UK across a range of academic institutions, industry partners and bio-tech companies. AbbVie commits funds and support to the Structural Genomics Consortium, a publicprivate partnership that enables the discovery of new medicines through open access research. This consortium includes Oxford University and the Wellcome Trust. INNOVATION IN MEDICINE APG members have been responsible for launching over 20 NEW in the UK between 2011 and 2015 5 In 2017 alone, the APG is conducting more than 500 CLINICAL TRIALS IN THE UK 6 Providing over 24,000 7 PATIENTS with the opportunity to benefit from innovative medicines The ten companies within the APG employ more than 14,000 people in highly skilled jobs 11. As each life sciences role support 3.4 jobs elsewhere in the UK economy, this reaches over 50,000 roles. APG member companies are based across over 40 regional sites in the UK covering R&D, manufacturing, packaging and commercial operations 12. With strong global competition for pharmaceutical investment, the APG works to ensure the UK is wellpositioned to retain its share. BMS is collaborating with researchers from the National Institute for Health Research (NIHR) to fund the world s largest preventative trial in arthritis. The study, based in the UK, is investigating whether targeted immunotherapy can prevent rheumatoid arthritis in individuals considered to be at high risk of developing the disease. P2 3 GROUP OVERVIEW 1 Based on 8 member contributions 2 Based on 8 member contributions 3 Based on 5 member contributions 4 Based on 8 member contributions 5 Based on 4 member contributions 6 Based on 9 member contributions 7 Based on 7 member contributions 8 Based on 8 member contributions 9 Based on 8 member contributions 10 Based on 5 member contributions 11 Based on 8 member contributions 12 Based on 7 member contributions 13 Based on 4 member contributions 14 Based on 9 member contributions 15 Based on 7 member contributions

APG members support for the life science ecosystem extends to more than just providing access to research, expertise and medicines. Our companies are also committed to supporting patients and the NHS to deliver improved standards and pathways of care. The imonitor, developed by Pfizer, is a secure website whereby healthcare professionals (HCPs) can remotely look after their patients with rheumatology conditions. The imonitor allows patients to provide HCPs with real-time information on their disease management. Specific markers set by the HCP then inform them of any treatment progression and allow concerns to be raised outside of appointments. MSD is supporting a collaboration called Insights for Care, which brings together the Heart of England NHS Foundation Trust, local GPs and Monitor Deloitte, to build a worldleading diabetes care collaboration in the Birmingham area. The partnership links nonidentifiable patient clinical data across the care pathway, in order to create a complete picture of a patient s interactions with the whole healthcare system over a number of years. In partnership with the leading patient group Diabetes UK, Lilly has developed the Diabetes Watch. This tool allows patients access to upto-date standards of diabetes care in their local area compared to the national average. The information relates to the minimum level of care that people with diabetes should receive based on Diabetes UK s 15 healthcare essentials. TO LEARN MORE, PLEASE VISIT WWW.APG.UK.COM P4 5 GROUP OVERVIEW

Opportunities for the UK to be a world leading life science ecosystem The UK is rightly regarded as a leading destination for scientific research. The APG has recently engaged in a series of conversations with 10 UK-educated members of the life sciences community now working in the US and affiliated with British Expats in Life Sciences. Each of them praised the quality of the scientific research that takes place in the UK, whilst also recognising the need to ensure a holistic and stable ecosystem from early stage research and development all the way to the rapid adoption of the latest innovations in the NHS, supported by a clear regulatory structure. TAKING INDUSTRY S TEMPERATURE ON THE LIFE SCIENCES ECOSYSTEM In 2015, APG members international headquarters responded to a survey on the UK life sciences environment across a range of areas. The survey explored global HQs sentiment on factors impacting in the external setting, which revealed the following: 16 NATIONAL ACCESS TO VERY POOR 1 1 2 3 4 5 Very poor Poor Average Good Excellent HOW TO CREATE A THRIVING LIFE SCIENCES ECOSYSTEM Views from those who have worked in both the US and UK markets Create the right environment and culture where life science innovation is given priority, and wrap around a system of incentives to energise it ANNALISA JENKINS, CEO, DIMENSION THERAPEUTICS The entire medicines life cycle needs to be supported from basic research through to commercialisation a lot of work needs to be done to ensure scientific advances reach the patient, as well as stimulate investment into further innovation MARTIN MACKAY, EVP AND GLOBAL HEAD OF R&D, ALEXION PHARMACEUTICALS CURRENT PRICING AND REIMBURSEMENT MECHANISMS FOR FLEXIBILITY OF IMMIGRATION RULES TAX ENVIRONMENT AND INCENTIVES 2.1 2.3 3.3 3.8 2 3 4 2.2 2.3 3.2 3.4 4.0 UPTAKE OF INNOVATIVE LOCAL ACCESS TO COST OF DOING BUSINESS (E.G. ENERGY, INSURANCE, SALARIES) ABILITY TO CONDUCT CLINICAL TRIALS 4.4 4.6 QUALITY OF THE SKILLS BASE Early access is vital. Other countries are getting the jump on the UK in terms of products that are a significant advancement and beyond proof of concept, making those products available before approval AKSHAY VAISHNAW, EVP R&D AND CMO, ALNYLAM PHARMACEUTICALS EMPLOYMENT REGULATIONS (E.G. MINIMUM WAGE, HEALTH AND SAFETY) 5 EXCELLENT QUALITY OF THE RESEARCH BASE, UNIVERSITIES AND RESEARCH CLUSTERS P6 7 GROUP OVERVIEW 16 Average score (/S) across all 9 responses, July 2015 January 2016

www.apg.uk.com apghanover@hanovercomms.com +44 20 7400 4480 The APG is chaired by Erik Nordkamp (General Manager, Pfizer) and supported by Vice Chair Mark Hicken (Managing Director, Janssen UK & Ireland).